X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with Dishman Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs DISHMAN PHARMA - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. DISHMAN PHARMA FRESENIUS KABI ONCO./
DISHMAN PHARMA
 
P/E (TTM) x 22.1 25.1 88.2% View Chart
P/BV x 3.1 3.3 93.0% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 FRESENIUS KABI ONCO.   DISHMAN PHARMA
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
DISHMAN PHARMA
Mar-16
FRESENIUS KABI ONCO./
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs176374 47.0%   
Low Rs79129 60.9%   
Sales per share (Unadj.) Rs37.7197.8 19.1%  
Earnings per share (Unadj.) Rs5.121.2 24.0%  
Cash flow per share (Unadj.) Rs6.734.7 19.4%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs42.5179.9 23.6%  
Shares outstanding (eoy) m158.2380.69 196.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.41.3 265.4%   
Avg P/E ratio x25.011.9 210.5%  
P/CF ratio (eoy) x18.97.2 261.2%  
Price / Book Value ratio x3.01.4 213.8%  
Dividend payout %09.4 0.0%   
Avg Mkt Cap Rs m20,13520,306 99.2%   
No. of employees `0001.20.8 139.0%   
Total wages/salary Rs m7035,355 13.1%   
Avg. sales/employee Rs Th5,176.219,252.7 26.9%   
Avg. wages/employee Rs Th610.46,459.5 9.4%   
Avg. net profit/employee Rs Th699.62,064.1 33.9%   
INCOME DATA
Net Sales Rs m5,96315,961 37.4%  
Other income Rs m18265 6.8%   
Total revenues Rs m5,98116,226 36.9%   
Gross profit Rs m1,4304,103 34.9%  
Depreciation Rs m2581,091 23.6%   
Interest Rs m-26944 -2.8%   
Profit before tax Rs m1,2162,334 52.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m342624 54.9%   
Profit after tax Rs m8061,711 47.1%  
Gross profit margin %24.025.7 93.3%  
Effective tax rate %28.126.7 105.3%   
Net profit margin %13.510.7 126.1%  
BALANCE SHEET DATA
Current assets Rs m5,10211,018 46.3%   
Current liabilities Rs m2,3859,517 25.1%   
Net working cap to sales %45.69.4 484.4%  
Current ratio x2.11.2 184.7%  
Inventory Days Days150110 135.8%  
Debtors Days Days11335 325.2%  
Net fixed assets Rs m5,14816,304 31.6%   
Share capital Rs m158161 98.0%   
"Free" reserves Rs m6,55612,907 50.8%   
Net worth Rs m6,73214,516 46.4%   
Long term debt Rs m9524,189 22.7%   
Total assets Rs m10,38829,805 34.9%  
Interest coverage x-45.83.5 -1,318.8%   
Debt to equity ratio x0.10.3 49.0%  
Sales to assets ratio x0.60.5 107.2%   
Return on assets %7.58.9 84.3%  
Return on equity %12.011.8 101.6%  
Return on capital %14.617.5 83.3%  
Exports to sales %74.524.8 300.4%   
Imports to sales %24.83.7 663.2%   
Exports (fob) Rs m4,4413,956 112.2%   
Imports (cif) Rs m1,477596 247.8%   
Fx inflow Rs m5,2984,952 107.0%   
Fx outflow Rs m1,772697 254.3%   
Net fx Rs m3,5254,255 82.9%   
CASH FLOW
From Operations Rs m1,2742,786 45.7%  
From Investments Rs m-1,204-1,529 78.8%  
From Financial Activity Rs m-196-941 20.8%  
Net Cashflow Rs m-126316 -39.9%  

Share Holding

Indian Promoters % 0.0 61.4 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 3.7 8.1%  
FIIs % 9.6 12.7 75.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 22.1 41.2%  
Shareholders   42,599 46,261 92.1%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   STRIDES SHASUN LTD  ELDER PHARMA  ALEMBIC LTD  ALEMBIC PHARMA  CADILA HEALTHCARE  

Compare FRESENIUS KABI ONCO. With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Tata Global Beverages Surges 8.3%(Closing)

Indian share markets snapped their losing streak of last week and finished the trading day on a strong note due to strong buying momentum in FMCG stocks, metal stocks and auto stocks.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 5-YR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS